Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).Adi Diab, Brendan D. Curti, Shilpa Gupta et al.|Journal of Clinical Oncology|2019Cited by 26
Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic MalignanciesNina Shah, Krina K. Patel, Miguel‐Angel Perales et al.|Future Oncology|2021Cited by 21
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumorsAdi Diab, Sandra P. D’Angelo, Brendan D. Curti et al.|Regular and Young Investigator Award Abstracts|2020Cited by 15
REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignanciesAdi Diab, Sandra P. D’Angelo, Mario Q. Marcondes et al.|Annals of Oncology|2018Cited by 7
Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 StudyCameron J. Turtle, Nina Shah, Krina K. Patel et al.|Blood|2021Cited by 6